Juan Sanchez - 11 Jun 2026 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Reporting relationship: Director
Issuer ticker: NVCT
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:11:03 UTC
Prior SEC filing: 06 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Juan Sanchez

Key filing fact

Juan Sanchez filed Form 4 for Nuvectis Pharma, Inc. (NVCT) on 12 Jun 2026.

Key facts

This page summarizes Juan Sanchez's Form 4 filing for Nuvectis Pharma, Inc. (NVCT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 12 Jun 2026, 16:11.

Change

Previous filing in this sequence was filed on 06 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002094238 Primary reporting owner

Sanchez Juan

Relationship: Director
Address: C/O NUVECTIS PHARMA, INC.,, 1 BRIDGE PLAZA, SUITE 275, FORT LEE
Signature: /s/ Juan Sanchez
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCT transaction

Common Stock

Award

Transaction value
Shares: +35,000
Change %: +45%
Price: $0.000000^*
Shares after: 113,380
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1, F2

NVCT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 415
Date: 11 Jun 2026
Ownership: As custodian for son

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Dr. Sanchez's continued service on the Company's Board of Directors on such dates.

Footnote F2

Includes 230 shares of restricted common stock that were inadvertently omitted from the initial holdings on Dr Sanchez's Form 3, filed on October 31, 2025.